🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

26 results for “Lei” Clear

  1. Sirolimus

    Ultragenyx UK Limited

    Lymphangioleiomyomatosis

    phase 3 small molecule completed

    1 trial

  2. Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules

    Lacuna Pharma Pty Ltd

    Newly diagnosed primary glioblastoma multiforme (ndGBM)

    phase 3 small molecule active

    1 trial

  3. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  4. Unesbulin

    PTC THERAPEUTICS, INC.

    Leiomyosarcoma

    phase 3 small molecule terminated

    2 trials

  5. Unesbulin

    PTC Therapeutics International Limited

    Leiomyosarcoma

    phase 3 small molecule terminated

    1 trial

  6. BAY1002670

    Bayer HealthCare AG

    Leiomyoma

    phase 2 small molecule completed

    1 trial

  7. Chemotherapy plus apatinib

    Lei Li

    Recurrent Cervical Carcinoma

    phase 2 small molecule completed

    1 trial

  8. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  9. EPI-743

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial

  10. GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  11. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-Schönlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  12. HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN, SALINE, HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN

    Takeda

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  13. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  14. Letrozole

    United Therapeutics Europe Ltd

    Lymphangioleiomyomatosis

    phase 2 small molecule completed

    1 trial

  15. Loratadina NORMON 10 mg Comprimidos EFG

    The George Institute

    Effect of loratadine in patients with lymphangioleiomyomatosis

    phase 2 small molecule active

    1 trial

  16. Placebo

    Universal Integrated

    Purpura, Schoenlein-Henoch

    phase 2 small molecule active

    1 trial

  17. Placebo

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial

  18. Prednisone

    Nanjing Children's Hospital

    Henoch-Schoenlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  19. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  20. allopurinol

    Ultragenyx UK Limited

    Leishmaniasis

    phase 2 small molecule completed

    1 trial

  21. ClinOleic (Baxter Healthcare, Deerfield, IL, USA)

    The First People's Hospital of Lianyungang

    Nutritional Supplement Toxicity

    phase 1 small molecule active

    1 trial

  22. Imatimib Mesylate

    United Therapeutics Europe Ltd

    Lymphangioleiomyomatosis (LAM)

    phase 1 small molecule active

    1 trial

  23. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  24. ACEI / ARB+finerenone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Henoch Schönlein Purpura Nephritis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources